Skip CCR Main Navigation National Cancer Institute National Cancer Institute U.S. National Institutes of Health
CCR - For Our Staff| Home |

Our Science – Restifo Website

Nicholas P. Restifo, M.D.

Selected Publications

1)  Dudley ME, Gross CA, Somerville RP, Hong Y, Schaub NP, Rosati SF, White DE, Nathan D, Restifo NP, Steinberg SM, Wunderlich JR, Kammula US, Sherry RM, Yang JC, Phan GQ, Hughes MS, Laurencot CM, Rosenberg SA.
Randomized Selection Design Trial Evaluating CD8+-Enriched Versus Unselected Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy for Patients With Melanoma.
J. Clin. Oncol. 2013.
2)  Chinnasamy D, Tran E, Yu Z, Morgan RA, Restifo NP, Rosenberg SA.
Simultaneous Targeting of Tumor Antigens and the Tumor Vasculature Using T Lymphocyte Transfer Synergize to Induce Regression of Established Tumors in Mice.
Cancer Res. 2013.
3)  Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, Dudley ME, Feldman SA, Yang JC, Sherry RM, Phan GQ, Hughes MS, Kammula US, Miller AD, Hessman CJ, Stewart AA, Restifo NP, Quezado MM, Alimchandani M, Rosenberg AZ, Nath A, Wang T, Bielekova B, Wuest SC, Akula N, McMahon FJ, Wilde S, Mosetter B, Schendel DJ, Laurencot CM, Rosenberg SA.
Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy.
J. Immunother. 36: 133-51, 2013.
4)  Kerkar SP, Leonardi AJ, van Panhuys N, Zhang L, Yu Z, Crompton JG, Pan JH, Palmer DC, Morgan RA, Rosenberg SA, Restifo NP.
Collapse of the Tumor Stroma is Triggered by IL-12 Induction of Fas.
Mol. Ther. [Epub ahead of print], 2013.
5)  Hanada K, Restifo NP.
Double or nothing on cancer immunotherapy.
Nat. Biotechnol. 31: 33-4, 2013.
6)  Muranski P, Restifo NP.
Essentials of Th17 cell commitment and plasticity.
Blood. 121: 2402-14, 2013.
7)  Lugli E, Gattinoni L, Roberto A, Mavilio D, Price DA, Restifo NP, Roederer M.
Identification, isolation and in vitro expansion of human and nonhuman primate T stem cell memory cells.
Nat Protoc. 8: 33-42, 2013.
8)  Crompton JG, Rao M, Restifo NP.
Memoirs of a reincarnated T cell.
Cell Stem Cell. 12: 6-8, 2013.
9)  Dudda JC, Salaun B, Ji Y, Palmer DC, Monnot GC, Merck E, Boudousquie C, Utzschneider DT, Escobar TM, Perret R, Muljo SA, Hebeisen M, Rufer N, Zehn D, Donda A, Restifo NP, Held W, Gattinoni L, Romero P.
MicroRNA-155 Is Required for Effector CD8(+) T Cell Responses to Virus Infection and Cancer.
Immunity. 38: 742-53, 2013.
10)  Yang S, Ji Y, Gattinoni L, Zhang L, Yu Z, Restifo NP, Rosenberg SA, Morgan RA.
Modulating the differentiation status of ex vivo-cultured anti-tumor T cells using cytokine cocktails.
Cancer Immunol. Immunother. 62: 727-36, 2013.
Click Here to View Expanded Bibliography.

This page was last updated on 5/25/2013.